Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...
Bio-Rad stock looks undervalued, boosted by its Sartorius stake, but headwinds and volatile guidance cap upside. Click here ...
Framing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has been under pressure recently, with the ...
The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...
Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter. The letter can be downloaded here. The fund returned -0.33% in the third ...
BIO benefits from steady Clinical Diagnostics demand and international growth, but macro pressures and currency headwinds could cap near-term upside.
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...
Bio-Rad Laboratories, Inc. BIO posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks Consensus Estimate by 1.74%. However, the bottom line increased 11.9% from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results